Pembrolizumab for Early Triple-Negative Breast Cancer


Schmid P., Cortes J. , Pusztai L., McArthur H., Kuemmel S., Bergh J., ...More

NEW ENGLAND JOURNAL OF MEDICINE, vol.382, no.9, pp.810-821, 2020 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 382 Issue: 9
  • Publication Date: 2020
  • Doi Number: 10.1056/nejmoa1910549
  • Title of Journal : NEW ENGLAND JOURNAL OF MEDICINE
  • Page Numbers: pp.810-821

Abstract

Background Previous trials showed promising antitumor activity and an acceptable safety profile associated with pembrolizumab in patients with early triple-negative breast cancer. Whether the addition of pembrolizumab to neoadjuvant chemotherapy would significantly increase the percentage of patients with early triple-negative breast cancer who have a pathological complete response (defined as no invasive cancer in the breast and negative nodes) at definitive surgery is unclear.